HIV Drugs Market Report and Forecast 2024-2032

HIV Drugs Market Outlook

The HIV drug market size attained a value of USD 33.54 billion in 2023. The market is anticipated to grow at a CAGR of 4.5% during the forecast period of 2024-2032 to attain a value of USD 49.85 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

HIV Drugs Market Overview

Human immunodeficiency virus (HIV) is a life-threatening condition that can be transferred from one person to another through blood and/or sexual contact. It damages the immune system by destroying CD-4 cells, making the body susceptible to infections and other diseases. The rising prevalence of HIV disease has positively impacted the demand for HIV drugs. According to the estimates by the World Health Organization (WHO), 39 million people are living with HIV. Approximately 0.7% of adults aged between 15-49 years are living with this condition worldwide. The growing population density of HIV-infected people has been instrumental in the development and introduction of HIV drugs.

The HIV drugs market growth is influenced by the rising government initiatives and campaigns to create awareness amongst people regarding the causes, symptoms, and treatments of the condition. At present, highly active antiretroviral therapy (HAART) is the most prescribed treatment. It has various combinations of one protease inhibitor and other drugs. These combinations aid in increasing the number of CD4+ cells and decreasing the amount of virus in the blood. The introduction of generic drug acts is another factor that is contributing to the demand for HIV drugs, as they are cost-effective and chemically identical to branded drugs. The market is experiencing increased advancement in the treatment technologies by the market players. Such advancements are significantly expected to drive the market growth.

Expedited Drug Development to Boost HIV Drugs Market Share

In October 2023, Gilead Sciences, Inc. revealed that Sunlenca® (lenacapavir),  their latest drug was well supported to treat multi-drug resistant (MDR) HIV in adults. Administered twice a year, Sunlenca is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, used in combination with other antiretrovirals. The drug is expected to be made available in oral as well as injectable mode of administration along with multiple dosage forms. The increasing advancements to bring customization and offer precise treatment to patients is poised to drive the market for HIV drugs in the forecast period.

Surge in Clinical Trials to Meet the Rising HIV Drugs Market Demand

The market growth is poised to be driven by the rising number of clinical trials and continued efforts by researchers to discover an effective treatment novel therapy to treat HIV. For instance, in April 2023, UC Davis Health researchers deployed CAR T cell therapy to treat patients suffering from HIV . Leveraging immunotherapy, the first patient was dosed with anti-HIV duoCAR T cells to stimulate the immune system and treat the condition. The clinical trial was designed for 9 candidates, divided in 3 cohorts wherein patients from each cohort underwent different treatment combinations. This is indicative of rising application of advanced and alternative therapies to treat the fatal disease.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

HIV Drugs Market Segmentation

Market Breakup by Medication Class

• Multi-Class Combination Drugs

• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

• Protease Inhibitors (Pls)

• Entry Inhibitors

• HIV Integrase Strand Transfer Inhibitors

• Others

Market Breakup by Distribution Channel

• Hospitals Pharmacies

• Drug stores and Retail Pharmacies

• Online Pharmacies

Market Breakup by End User

• Hospitals

• Clinics

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom

• Germany
• France
• Italy
• Spain
• United Kingdom

• Japan

• China

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

HIV Drugs Market Regional Analysis

Geographically, North America is expected to lead the market share in the forecast period. The regional growth can be attributed to a well-established healthcare system, and the growing adoption of advanced treatment options for the HIV-infected population. The HIV drugs market size is significantly impacted by the increased number of research and development initiatives for new drug launches.

In September 2023, researchers at Johns Hopkins found a new injectable solution that could help manage HIV, unlike any currently available methods in the market. This new solution self-assembles into a gel under the right conditions. It releases a steady dose of the anti-HIV drug lamivudine over six weeks. The major issue that patients face while following an HIV treatment regimen is the daily management of the doses. However, this new gel treatment is poised to help people living with HIV to have a new therapy that doesn't require a daily pill regimen to prevent AIDS, making it less stressful and easy to follow.

The Asia Pacific region is also poised to experience significant HIV drugs market growth, owing to increasing infrastructure improvements and emphasis on spreading awareness about the condition amongst marginalised communities.

HIV Drugs Market: Competitor Landscape

In February 2022, ViiV Healthcare , the global specialist HIV company, announced the US Food and Drug Administration (FDA) approval for Cabenuva (cabotegravir, rilpivirine) for every two months dosing for the treatment of HIV-1 in virologically suppressed adults. The drug constitutes an extended-release injectable suspension in a single vial dose, making it suitable for easy administration. The approval was based on the positive results from ATLAS-2M phase IIIb trial.

The key features of the HIV drugs market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• ViiV Healthcare Group of Companies

• Gilead Sciences, Inc.

• GSK Plc.

• Merck & Co., Inc.

• Bristol-Myers Squibb Company

• Johnson & Johnson Services, Inc.

• Boehringer Ingelheim International GmbH

• AbbVie Inc.

• Genentech, Inc.

• Mylan N.V.

• CytoDyn Inc.

• Daichii Sankyo Company, Limited

• Pfizer Inc.

• Shantou Huatai Pharmaceutical Co., Ltd.

• Shengzhen Chongway Biotechnology Co., Ltd

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

HIV Drugs Market Report Snapshots

HIV Drugs Market Size

HIV Drugs Market Analysis

HIV Drugs Companies